

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**M.7682 - GOLDMAN SACHS / ALTOR / HAMLET**

**SECTION 1.2**

**Description of the concentration**

On 10 July 2015, the Commission received notification of a proposed concentration pursuant to which The Goldman Sachs Group, Inc. (“Goldman Sachs”) and Altor Fund IV (“Altor”) will acquire joint control of Hamlet Protein A/S (“Hamlet”).

- Goldman Sachs is a global investment banking, securities and investment management firm.
- Altor is a private equity investment firm which focuses on investments in the mid-market segment of the Nordic region.
- Hamlet is engaged in the development, production, sale and distribution of soya protein for animal nutrition.